T-cell receptor-Major Histocompatibility Complex signaling complex (TCR-MHC complex)

The interaction between T cells and antigen-presenting cells (APCs) via the MHC class I/II–TCR complex and co-stimulatory molecules is the fundamental mechanism of the adaptive immune response (Janeway et al., 2001). This process, often referred to as the "two-signal model," requires the recognition of a peptide-MHC complex by the T-cell receptor (Signal 1) and the engagement of co-stimulatory or co-inhibitory receptors like CD28 or PD-1 (Signal 2) (Sharpe & Freeman, 2002). Signal 1 provides the necessary specificity for the immune response, while Signal 2 determines the magnitude and functional outcome of T-cell activation. Dysregulation of this system is central to the pathogenesis of autoimmune diseases, where T cells are inappropriately overactive, and cancer, where T cells are often suppressed or "exhausted" (Chen & Flies, 2013). Therapeutic strategies targeting these molecules include checkpoint inhibitors that block inhibitory signals to enhance anti-tumor activity and fusion proteins or antibodies that block co-stimulation to treat inflammatory conditions. For example, drugs like pembrolizumab target the PD-1/PD-L1 axis to restore T-cell function in oncology, while abatacept targets the CD80/86-CD28 axis to reduce inflammation in rheumatoid arthritis. Understanding this complex interplay is crucial for developing precision immunotherapies that can either boost or dampen the immune system depending on the clinical context.

Other names

T-cell activation pathwayImmune synapseSignal 1 and Signal 2 signalingMHC-TCR-Co-stimulation axis

Modulation of T-cell activation and effector function by targeting the interaction between T-cell receptors, MHC molecules, and secondary co-signaling proteins.